Evidence map›Paper›PMID 40971958›Full record

ArticlePloS one2025

Detection and score grading for prostate adenocarcinoma using semantic segmentation.

Kasikrit Damkliang, Paramee Thongsuksai, Thakerng Wongsirichot, Kanita Kayasut

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kasikrit DamkliangDivision of Computational Science, Faculty of Science, Prince of Songkla University, Hat Yai, Songkhla, Thailand.ORCID 0000-0002-5342-7302
Paramee ThongsuksaiDepartment of Pathology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
Thakerng WongsirichotDivision of Computational Science, Faculty of Science, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
Kanita KayasutDepartment of Pathology, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prostate cancer is a major global health challenge. In this study, we present an approach for the detection and grading of prostate cancer through the semantic segmentation of adenocarcinoma tissues, specifically focusing on distinguishing between Gleason patterns 3 and 4. Our method leverages deep learning techniques to improve diagnostic accuracy and enhance patient treatment strategies. We developed a new dataset comprising 100 digitized whole-slide images of prostate needle core biopsy specimens, which are publicly available for research purposes. Our proposed model integrates dilated attention mechanisms and a residual convolutional U-Net architecture to enhance the richness of feature representations. Class imbalance is addressed using pixel expansion and class weights, and a five-fold cross-validation method ensures robust training and validation. In model ensemble evaluation, the model achieves an average Dice of 0.87 and accuracy of 0.92 on the cross-validation held-out folds. When applied to completely unseen, external test data, the model demonstrates an average Dice of 0.64 and accuracy of 0.81. Segmentation and grading results were validated by a team of expert pathologists. Based on experimental results, this study demonstrates the potential of our proposed method and model as a valuable tool for the detection and grading of prostate cancer in clinical settings.

Indexed as

AdenocarcinomaProstatic NeoplasmsDeep LearningHumansMaleNeoplasm GradingProstateSemantics

Identifiers

PMID40971958
PMCPMC12448973

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.